MGC Pharmaceuticals - Director/PDMR Shareholding
18/05/2023 12:00
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230518:nRSR9127Za&default-theme=true
RNS Number : 9127Z MGC Pharmaceuticals Limited 18 May 2023
MGC Pharmaceuticals Ltd.
PDMR Notification
18 May 2023
ASX, LSE: MXC
MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company') wishes to advise that
the following Persons Discharging Managerial Responsibilities (PDMR) have
dealt with shares in MGC Pharma, and this notification is made in accordance
the UK Market Abuse Regulations.
1 Details of the person discharging managerial responsibilities/person closely
associated
(a) Name Nicole Godresse
2 Reason for the notification
(a) Position Global Chief Sales Officer MGC Medical
(b) Initial notification/amendment Initial
(c) If amendment: reason n/a
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
Full name of entity MGC Pharmaceuticals Limited
Legal Entity Identifier Code 213800HRE3FQJ6RK4H10
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; (iv) each place
where transactions have been conducted
(a) Description of the financial instrument, type of instrument Fully Paid Ordinary Shares
(b) Identification Code (ISIN) AU000000MXC6
(c) Nature of transaction Disposal of shares
(d) Currency Price Volume Total
AUD $0.007 876,636 $6,136
Aggregated information
AUD $0.007 876,636 $6,136
(e) Date of transaction 2023-05-16
(f) Place of transaction Australian Stock Exchange
1 Details of the person discharging managerial responsibilities/person closely
associated
(a) Name Amir Polak
2 Reason for the notification
(a) Position Chief Pharmaceutical Development Officer
(b) Initial notification/amendment Initial
(c) If amendment: reason n/a
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
Full name of entity MGC Pharmaceuticals Limited
Legal Entity Identifier Code 213800HRE3FQJ6RK4H10
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; (iv) each place
where transactions have been conducted
(a) Description of the financial instrument, type of instrument Fully Paid Ordinary Shares
(b) Identification Code (ISIN) AU000000MXC6
(c) Nature of transaction Disposal of shares
(d) Currency Price Volume Total
AUD $0.007 500,000 $3,500
Aggregated information
AUD $0.007 500,000 $3,500
(e) Date of transaction 2023-05-17
(f) Place of transaction Australian Stock Exchange
--Ends-
Authorised for release by the Managing Director, for further information
please contact:
MGC Pharmaceuticals Ltd MGC Pharmaceuticals Ltd
Roby Zomer Arron Canicais / Rowan Harland
CEO & Managing Director Joint Company Secretaries
+61 8 6382 3390 +61 8 6382 3390
info@mgcpharma.co.uk (mailto:info@mgcpharma.co.uk) info@mgcpharma.co.uk (mailto:info@mgcpharma.co.uk)
UK PR Advisors UK Brokers
Tavistock Peterhouse Capital
Charles Vivian / Tim Pearson Charles Goodfellow / Lucy Williams
+44 207 920 3150 +44 207 469 0930
mgcpharma@tavistock.co.uk (mailto:mgcpharma@tavistock.co.uk) cg@peterhousecap.com (mailto:cg@peterhousecap.com) / lw@peterhousecap.com
(mailto:lw@peterhousecap.com)
UK Financial and Corporate Advisor
SW4 Partners
Rupert Fane / Nilesh Patel
rupert@sw4partners.com (mailto:rupert@sw4partners.com) /
nilesh@sw4partners.com (mailto:nilesh@sw4partners.com)
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END DSHBGGDULUBDGXI
Recent news on Argent BioPharma
See all newsBrief: Argent Biopharma Enters Long Term Aquiol Licensing And Supply Agreement
Brief: Argent Biopharma Secures A$11M Financing Facility To Complete Strategic Acquisition
Brief: Argent Is Growing Through M&A Projected Merged Company Value Of $100M In Ac8 Asset Acquisition
Australia's Argent BioPharma set for best day in a year on AusCann deal
Brief: Argent Biopharma To Acquire Core Operating Assets And IP Portfolio Of Auscann Group